I got my questions answered. My ?'s is line one with the ?
at the end. My cut and paste noted them all 1. But they are 1-2-3. I appreciate the answers. But the next time we can look behind the curtain at the Great Wizard, is next Feb. But the ship will not arrive at its destination (paradise or ice berg) for a few years. YIKES! It is gonna be a long wait.
I replied back to the sales effort note of "government/reimbursement consulting services". I simply asked, how can we get this on the Aussie Medicare rebate schedule.
- What marketing and/or sales tasks are being undertaken to generate FebriDx sales aside from signing distributors?
Lumos is pursuing the path to establish FebriDx as a standard ofcare in the US. This path is a methodical process that will take several yearsto complete. Currently, FebriDx is cleared to be marketed in moderately complexcertified testing environments. These locations are typically in hospitals andurgent care/emergency rooms. As most of these locations are part of hospitals,they have well documented and practiced clinical pathways. Since FebriDxis a novel test with a unique label, establishing the test in a hospitalclinical pathway is a systematic process which requires physician education,clinical awareness, and work with each individual healthcare institution tobuild the clinical case. The case is then validated for the clinical andeconomic benefit to have FebriDx established as an authorized/ accepted part oftheir acute respiratory infection pathway. In addition to a clinical pathwayfocus, sales and marketing has also allocated resources to stimulate FebriDxsales via digital marketing, physician/clinic tradeshows, AMR symposiums, newfield sales hires, government/reimbursement consulting services, and socialmedia brand awareness campaigns.
- Why where there such a low volume of FebriDx sales in q1 just released?
The US is by far our largest market and hence the US flu season -typically Oct through Feb/March is our key selling period. Lumos launchedFebriDx in January 2024. As we enter our first full flu season in the US, ourobjective remains to appoint national and regional distributors to obtain USmarket access. Lumos has made several announcements as distributors, likeThermo Fisher, have been secured. Please refer to the answer in the previousquestion, which best addresses the expected sales ramp profile until this noveltest is more readily embraced clinically and CLIA waiver is obtained. As youcan appreciate this process takes time to execute.
- We are nearly half way through q2, are the sales for FebriDx in q2, to date, more than the entirety of q1?
As you can understand, ASX disclosure rules prevent us fromsharing detailed information on an individual basis, except through officialASX lodgement channels. The next update on sales progress will be provided withthe Q2 FY25 results, scheduled for release in late January 2025.
(20min delay)